New and emerging pharmacotherapy for duchenne muscular dystrophy: a focus on synthetic therapeutics-Reference-Cited by-同舟云学术

New and emerging pharmacotherapy for duchenne muscular dystrophy: a focus on synthetic therapeutics

Published:2020-03-05 Issue:7 Volume:21 Page:841-851
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Grages Sharon M.¹,Bell Michael¹,Berlau Daniel J.¹^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, Regis University School of Pharmacy, Denver, Colorado

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2020.1732350

Reference99 articles.

1. Duchenne muscular dystrophy (DMD) | muscular dystrophy association. [Internet]. [cited 2019 Oct 27]. Available from: https://www.mda.org/disease/duchenne-muscular-dystrophy

2. About duchenne muscular dystrophy | espeRare foundation. [Internet]. [cited 2019 Oct 27]. Available from: https://esperare.org/en/about-duchenne-muscular-dystrophy

3. Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy

4. Mechanisms on inhibition of polyethylene electrical tree aging: a theoretical study

5. Duchenne UK. Girls living with duchenne | duchenne UK. [Internet]. 2019 [cited 2020 Feb 4]. Available from: https://www.duchenneuk.org/girls-living-with-duchenne

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How Can Proteomics Help to Elucidate the Pathophysiological Crosstalk in Muscular Dystrophy and Associated Multi-System Dysfunction?;Proteomes;2024-01-16

2. Cellular pathogenesis of Duchenne muscular dystrophy: progressive myofibre degeneration, chronic inflammation, reactive myofibrosis and satellite cell dysfunction;European Journal of Translational Myology;2023-10-16

3. Antisense Oligonucleotides: Concepts and Pharmaceutical Applications;Borneo Journal of Pharmacy;2023-02-28

4. Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy;Expert Opinion on Pharmacotherapy;2022-10-03

5. Characterisation of Progressive Skeletal Muscle Fibrosis in the Mdx Mouse Model of Duchenne Muscular Dystrophy: An In Vivo and In Vitro Study;International Journal of Molecular Sciences;2022-08-05